The plant, which will mark Roche’s second for branded medicines in the country, will mainly be used for domestic production of the eye med Vabysmo, which goes by the commercial moniker Luoshijia ...

Roche has claimed a third approval from the FDA for its eye disease therapy Vabysmo – already its fastest-growing product – that could make it an option for hundreds of thousands of additional ...

Eylea HD can be administered at a maximum of every 16 weeks for AMD and DME and every 12 weeks for DR. A new dosing option would give Eylea HD a much-needed boost against Vabysmo, which can be ...

Investors will look at commentary on blockbuster eye drug Vabysmo's sales performance, which could slow down in the U.S. due to potential Medicare funding issues affecting patients, UBS and ...

Roche’s Genentech unit has said will reintroduce its Susvimo ... and Roche’s new drug Vabysmo (faricimab), currently require injections every month, at least initially. Thereafter, dosing ...

eye drug Vabysmo and allergy treatment Xolair. Quarterly group revenues came in at 15.44 billion Swiss francs ($18.64 billion), slightly above average market expectations of about 15.4 billion ...

Please note that Regeneron co-developed Eylea with the HealthCare unit of Bayer AG BAYRY ... Eylea sales have been under pressure for some time now due to competition from Vabysmo. We note that ...

FRANKFURT (Reuters) -Swiss drugmaker Roche said on Thursday its first-quarter sales rose a forecast-beating 7% driven by breast cancer drug Phesgo, eye drug Vabysmo and allergy treatment Xolair.